Chapter 7: Description of miscan-lung, the erasmus mc lung cancer microsimulation model for evaluating cancer control interventions

Risk Analysis

Volumn 32, Issue SUPPL.1, 2012, Pages

  Schultz, F W ^a   Boer, R ^a   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Evaluating cancer control interventions; Lung cancer

Indexed keywords

CANCER CONTROL; COMPARATIVE STUDIES; LIFE HISTORY; LUNG CANCER; MICROSIMULATION; MICROSIMULATION MODELS; MODEL FIT; RISK FACTORS; TOBACCO CONTROL; TWO-STAGE CLONAL EXPANSION MODEL; WORKING GROUPS;

DISEASE CONTROL; DISEASES; ESTIMATION; TOBACCO;

BIOLOGICAL ORGANS;

CANCER; CARCINOGEN; COHORT ANALYSIS; COMPARATIVE STUDY; DEMOGRAPHIC TREND; DISEASE CONTROL; DISEASE INCIDENCE; DISEASE PREVALENCE; HEALTH SERVICES; MORTALITY; POPULATION MODELING; RISK FACTOR; SMOKING; STOCHASTICITY; TOBACCO;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPUTER PROGRAM; COMPUTER SIMULATION; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; PUBLIC HEALTH; RISK FACTOR; SMOKING; STATISTICAL MODEL; STATISTICS; TOBACCO; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMPUTER SIMULATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; PUBLIC HEALTH; RISK FACTORS; SMOKING; SOFTWARE; STOCHASTIC PROCESSES; TOBACCO PRODUCTS; UNITED STATES;

UNITED STATES;

NICOTIANA TABACUM;

EID: 84864947583     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2011.01752.x     Document Type: Article

References (29)

1. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Computer Methods and Programs in Biomedicine, 1985; 20:79-93.
2. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Computers and Biomedical Research, 1999; 32:13-33.
3. Van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. British Journal of Cancer, 1991; 64:559-565.
4. De Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. Journal of the National Cancer Institute, 1995; 87:1217-1223.
5. Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JDF, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer, 2006; 107(7):1624-1633.
6. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute, 2003; 95:868-878.
7. Moolgavkar SH, Venzon DJ. Two-event models for carcinogenesis: Incidence curves for childhood and adult tumors. Mathematical Biosciences, 1979; 47:55-77.
8. Moolgavkar SH, Knudson AG. Mutation and cancer: A model for human carcinogenesis. Journal of the National Cancer Institute, 1981; 66:1037-1052.
9. Hazelton WD, Clements MS, Moolgavkar SH. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiology, Biomarkers & Prevention, 2005; 14:1171-1181.
10. Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the nurses' health and the health professionals' follow-up studies using a multistage carcinogenesis model. Cancer Causes and Control, 2008; 19:317-328.
11. CISNET Lung Cancer Model Profiles, Erasmus Medical Center (in particular Section "Smoking_Base_Case16Feb09" is specific to the present implementation of MISCAN-lung). Available at: http://cisnet.cancer.gov/lung/profiles.html, Accessed on February 25, 2010.
12. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. British Journal of Cancer, 1954; 8:1-12.
13. Moolgavkar SH, Luebeck EG. Two event model for carcinogenesis: Biological, mathematical, and statistical considerations. Risk Analysis, 1990; 10:323-341.
14. Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT. Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. Risk Analysis, 2012; 32(S1):S51-S68.
15. Carter SB, Gartner SS, Haines MR, Olmstead AL, Sutch R, Wright G (eds). Historical Statistics of the United States. Millennial Edition, Vol. 1 Table Ab11-30. New York: Cambridge University Press, 2006.
16. NCI-SEER. 2000 US Standard Population (Census P25-1130): Single Ages. Available at: http://seer.cancer.gov/stdpopulations/stdpop.singleages.html, Accessed on August 20, 2009.
17. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: The Mayo program. Journal of Occupational Medicine, 1986; 28:746-750.
18. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet, 2003; 362:847-852.
19. Adhikari B, Kahende J, Malarcher A, Pechacek T, Tong V (National Center for Chronic Disease Prevention and Health Promotion, CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. Morbidity and Mortality Weekly Report, 2008; 57:1226-1228. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5745a3.htm, Accessed August 26, 2009.
20. Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the United States Journal of the National Cancer Institute, 1991; 83:1142-1148.
21. Shopland DR (ed). The Health Consequences of Smoking: Cancer; A Report of the Surgeon General. United States. Public Health Service. Office on Smoking and Health, 1982, Available at: http://profiles.nlm.nih.gov/NN/B/C/D/W/, Accessed August 26, 2009.
22. Mackay J, Eriksen M. The Tobacco Atlas. Brighton, UK: Myriad Editions Limited, 2002 for the World Health Organization. Availalble at: http://www.who.int/tobacco/resources/publications/tobacco_atlas/en/index .html, Accessed on November 17, 2009.
23. Fadnes L, Taube A, Tylleskär T. How to identify information bias due to self-reporting in epidemiological research. Internet Journal of Epidemiology, 2009; 7(2).
24. Hatziandreu EJ, Pierce JP, Fiore MC, Grise V, Novotny TE, Davis RM. The reliability of self-reported cigarette consumption in the United States. American Journal of Public Health, 1989; 9:1020-1023.
25. Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking and daily cigarette consumption: Results from Cancer Prevention Study II. Cancer Research, 2003; 63:6556-6562.
26. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in the histopathology of lung cancer. Journal of the National Cancer Institute, 1997; 89:1580-1586.
27. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: Analysis of a prospective cohort study. Lancet Oncology, 2008; 9:649-656.
28. Harkness EF, Brewster DH, Kerr KM, Fergusson RJ, MacFarlane GJ. Changing trends in incidence of lung cancer by histologic type in Scotland. International Journal of Cancer, 2002; 102:179-183.
29. Kabir Z, Connolly GN, Clancy L. Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. Ulster Medical Journal, 2008; 77:31-35.